Synergy Pharmaceuticals LLC
(Other OTC/NBB : SGYP)

... ...
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
HZNPHorizon Therapeutics Plc -1.74%77.545.6%$201.44m
VRXValeant Pharmaceuticals International, Inc. -2.01%25.8814.1%$152.28m
CTLTCatalent, Inc. -0.97%114.122.1%$112.56m
BHCBausch Health Cos., Inc. -2.01%25.880.0%$89.11m
JAZZJazz Pharmaceuticals Plc 0.40%166.482.4%$87.69m
UTHRUnited Therapeutics Corp. 1.67%170.0514.1%$65.84m
SAGESAGE Therapeutics, Inc. -4.66%92.257.6%$55.57m
ACSTAcasti Pharma, Inc. -4.93%0.600.2%$50.04m
GWPHGW Pharmaceuticals Plc 0.23%138.156.1%$48.51m
AMRNAmarin Corp. Plc -0.33%6.111.5%$47.34m
PRGOPerrigo Co. Plc -0.63%44.376.8%$47.04m
ISRIsoRay, Inc. 4.62%2.002.5%$45.53m
ICLRICON plc -0.47%209.684.2%$42.69m
ENDPEndo International Plc -0.62%7.188.7%$37.84m
ARGXargenx SE 0.04%282.290.0%$37.79m

Company Profile

Synergy Pharmaceuticals Inc., headquartered in New York, NY with laboratories in Doylestown, PA, is a biopharmaceutical company focused on the research and development of novel therapies for the treatment of chronic idiopathic constipation, irritable bowel syndrome with constipation and other difficult-to-treat gastrointestinal (GI) conditions. Synergy’s lead drug, plecanatide, and next-generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate cyclase-C (“GC-C”) agonists.